Lumos Pharma Inc (LUMO)
2.25
-0.04
(-1.75%)
USD |
NASDAQ |
May 31, 16:00
2.27
+0.02
(+0.89%)
After-Hours: 20:00
Lumos Pharma Research and Development Expense (TTM): 29.34M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 29.34M |
| December 31, 2023 | 26.46M |
| September 30, 2023 | 24.67M |
| June 30, 2023 | 23.75M |
| March 31, 2023 | 22.23M |
| December 31, 2022 | 22.08M |
| September 30, 2022 | 20.58M |
| June 30, 2022 | 20.56M |
| March 31, 2022 | 15.81M |
| December 31, 2021 | 16.25M |
| September 30, 2021 | 15.35M |
| June 30, 2021 | 13.31M |
| March 31, 2021 | 11.96M |
| December 31, 2020 | 9.206M |
| September 30, 2020 | 7.874M |
| June 30, 2020 | 7.001M |
| March 31, 2020 | 6.119M |
| December 31, 2019 | 5.669M |
| September 30, 2019 | 10.26M |
| June 30, 2019 | 16.63M |
| March 31, 2019 | 26.84M |
| December 31, 2018 | 45.69M |
| September 30, 2018 | 57.43M |
| June 30, 2018 | 68.34M |
| March 31, 2018 | 74.46M |
| Date | Value |
|---|---|
| December 31, 2017 | 69.87M |
| September 30, 2017 | 71.90M |
| June 30, 2017 | 77.88M |
| March 31, 2017 | 87.09M |
| December 31, 2016 | 93.30M |
| September 30, 2016 | 88.60M |
| June 30, 2016 | 86.65M |
| March 31, 2016 | 75.37M |
| December 31, 2015 | 71.41M |
| September 30, 2015 | 68.55M |
| June 30, 2015 | 56.94M |
| March 31, 2015 | 47.28M |
| December 31, 2014 | 35.69M |
| September 30, 2014 | 28.97M |
| June 30, 2014 | 24.20M |
| March 31, 2014 | 22.76M |
| December 31, 2013 | 22.71M |
| September 30, 2013 | 21.99M |
| June 30, 2013 | 20.65M |
| March 31, 2013 | 20.35M |
| December 31, 2012 | 17.84M |
| September 30, 2012 | 17.33M |
| June 30, 2012 | 15.85M |
| March 31, 2012 | 14.90M |
| December 31, 2011 | 14.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
5.669M
Minimum
Dec 2019
29.34M
Maximum
Mar 2024
16.26M
Average
16.03M
Median
Research and Development Expense (TTM) Benchmarks
| icad Inc | 5.169M |
| Perspective Therapeutics Inc | 24.91M |
| Palatin Technologies Inc | 25.13M |
| Bio-Path Holdings Inc | 9.907M |
| PDS Biotechnology Corp | 28.62M |